MIPSS70+ v2.0 predicts long-term survival in myelofibrosis after allogeneic HCT with the Flu/Mel conditioning regimen.


Journal

Blood advances
ISSN: 2473-9537
Titre abrégé: Blood Adv
Pays: United States
ID NLM: 101698425

Informations de publication

Date de publication:
08 01 2019
Historique:
received: 27 09 2018
accepted: 07 12 2018
entrez: 10 1 2019
pubmed: 10 1 2019
medline: 10 1 2020
Statut: ppublish

Résumé

Although allogeneic hematopoietic cell transplantation (allo-HCT) is the only curative treatment for myelofibrosis (MF), data are limited on how molecular markers predict transplantation outcomes. We retrospectively evaluated transplantation outcomes of 110 consecutive MF patients who underwent allo-HCT with a fludarabine/melphalan (Flu/Mel) conditioning regimen at our center and assessed the impact of molecular markers on outcomes based on a 72-gene next-generation sequencing panel and Mutation-Enhanced International Prognostic Scoring System 70+ v2.0 (MIPSS70+ v2.0). With a median follow-up of 63.7 months, the 5-year overall survival (OS) rate was 65% and the nonrelapse mortality (NRM) rate was 17%. In mutational analysis, JAK2 V617F and ASXL1 mutations were the most common. By univariable analysis, higher Dynamic International Prognostic Scoring System scores, unrelated donor type, and very-high-risk cytogenetics were significantly associated with lower OS. Only CBL mutations were significantly associated with lower OS (hazard ratio [HR], 2.64;

Identifiants

pubmed: 30622146
pii: bloodadvances.2018026658
doi: 10.1182/bloodadvances.2018026658
pmc: PMC6325305
doi:

Substances chimiques

Vidarabine Phosphate 106XV160TZ
fludarabine phosphate 1X9VK9O1SC
Melphalan Q41OR9510P

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

83-95

Subventions

Organisme : NCI NIH HHS
ID : P30 CA033572
Pays : United States

Informations de copyright

© 2019 by The American Society of Hematology.

Références

Blood. 1996 Aug 1;88(3):1013-8
pubmed: 8704209
Leukemia. 2018 May;32(5):1189-1199
pubmed: 29472717
Biol Blood Marrow Transplant. 2014 Jan;20(1):89-97
pubmed: 24161923
Blood. 2010 Apr 8;115(14):2891-900
pubmed: 20008300
Clin Lymphoma Myeloma Leuk. 2016 Aug;16 Suppl:S105-13
pubmed: 27521306
Blood. 2015 Feb 19;125(8):1333-8
pubmed: 25593335
Blood. 2017 Feb 9;129(6):667-679
pubmed: 28028029
Biol Blood Marrow Transplant. 2017 Jul;23(7):1095-1101
pubmed: 28389256
Biol Blood Marrow Transplant. 2010 Mar;16(3):358-67
pubmed: 19879949
Mayo Clin Proc. 2012 Jan;87(1):25-33
pubmed: 22212965
Am J Hematol. 2016 Dec;91(12):1262-1271
pubmed: 27870387
Leukemia. 2014 Sep;28(9):1804-10
pubmed: 24549259
Biol Blood Marrow Transplant. 2018 Sep;24(9):1828-1835
pubmed: 29753158
Nature. 2009 Aug 13;460(7257):904-8
pubmed: 19620960
Blood. 2009 Mar 26;113(13):2895-901
pubmed: 18988864
Blood Adv. 2016 Nov 30;1(2):105-111
pubmed: 29296803
Bone Marrow Transplant. 1995 Jun;15(6):825-8
pubmed: 7581076
J Clin Oncol. 2018 Jun 10;36(17):1769-1770
pubmed: 29708808
Blood. 2014 Aug 14;124(7):1183-91
pubmed: 24963042
Biol Blood Marrow Transplant. 2010 Feb;16(2):281-6
pubmed: 19786111
Genet Med. 2015 May;17(5):405-24
pubmed: 25741868
J Clin Oncol. 2011 Feb 1;29(4):392-7
pubmed: 21149668
Am J Hematol. 2018 May;93(5):649-654
pubmed: 29388258
Blood. 2016 May 19;127(20):2391-405
pubmed: 27069254
Haematologica. 2017 Dec;102(12):2030-2038
pubmed: 28971906
J Mol Diagn. 2017 Jan;19(1):4-23
pubmed: 27993330
Biol Blood Marrow Transplant. 2006 Nov;12(11):1161-8
pubmed: 17085309
Haematologica. 2014 May;99(5):916-21
pubmed: 24389309
Blood. 2011 Aug 25;118(8):2069-76
pubmed: 21725052
Biol Blood Marrow Transplant. 2015 Mar;21(3):389-401.e1
pubmed: 25529383
Blood. 2009 Dec 17;114(26):5264-70
pubmed: 19812383
J Clin Oncol. 2018 Feb 1;36(4):310-318
pubmed: 29226763
Leukemia. 2014 Jul;28(7):1472-7
pubmed: 24402162
Blood. 2012 Aug 16;120(7):1367-79
pubmed: 22700718

Auteurs

Haris Ali (H)

Department of Hematology and Hematopoietic Cell Transplantation.

Ibrahim Aldoss (I)

Department of Hematology and Hematopoietic Cell Transplantation.

Dongyun Yang (D)

Division of Biostatistics, Department of Information Sciences.

Sally Mokhtari (S)

Department of Clinical Translational Program Development, and.

Samer Khaled (S)

Department of Hematology and Hematopoietic Cell Transplantation.

Ahmed Aribi (A)

Department of Hematology and Hematopoietic Cell Transplantation.

Michelle Afkhami (M)

Department of Pathology, City of Hope, Duarte, CA.

Monzr M Al Malki (MM)

Department of Hematology and Hematopoietic Cell Transplantation.

Thai Cao (T)

Department of Hematology and Hematopoietic Cell Transplantation.

Matthew Mei (M)

Department of Hematology and Hematopoietic Cell Transplantation.

Margaret O'Donnell (M)

Department of Hematology and Hematopoietic Cell Transplantation.

Amandeep Salhotra (A)

Department of Hematology and Hematopoietic Cell Transplantation.

Vinod Pullarkat (V)

Department of Hematology and Hematopoietic Cell Transplantation.

Lixin Yang (L)

Department of Pathology, City of Hope, Duarte, CA.

Anthony S Stein (AS)

Department of Hematology and Hematopoietic Cell Transplantation.

Guido Marcucci (G)

Department of Hematology and Hematopoietic Cell Transplantation.

Stephen J Forman (SJ)

Department of Hematology and Hematopoietic Cell Transplantation.

Ryotaro Nakamura (R)

Department of Hematology and Hematopoietic Cell Transplantation.

Raju Pillai (R)

Department of Pathology, City of Hope, Duarte, CA.

David Snyder (D)

Department of Hematology and Hematopoietic Cell Transplantation.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH